Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petr Husa

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Antiviral Research|December 9, 2017
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countriesHakan Leblebicioglu, Joop E Arends, Resat Ozaras, et al.
Influenza and Other Respiratory Viruses|August 15, 2024
Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|January 19, 2024
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, et al.
Microorganisms|July 2, 2021
Clinical Characteristics of Patients with Tick-Borne Encephalitis (TBE): A European Multicentre Study from 2010 to 2017Benno Kohlmaier, Nina A Schweintzger, Manfred G Sagmeister, et al.
Influenza and Other Respiratory Viruses|March 9, 2025
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024Liliana Antunes, Madelyn Rojas-Castro, Marcos Lozano, et al.
Iscience|December 11, 2025
Genome-wide association study identifies <i>ABCG1</i> as a susceptibility locus for tick-borne encephalitisPiyush G Gampawar, Manfred G Sagmeister, Daniel Růžek, et al.
BMC Medicine|November 4, 2025
Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24Angela Mary Catherine Rose, Nathalie Nicolay, Clara Mazagatos, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 23, 2024
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024Marine Maurel, Jennifer Howard, Esther Kissling, et al.
Vaccine|May 20, 2023
VACCELERATE Site Network: Real-time definition of clinical study capacity in EuropeJon Salmanton-García, Pauline Wipfler, Paula Valle-Simón, et al.
Vaccines|December 23, 2023
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE ConsortiumDimitrios Poulimeneas, Markela Koniordou, Dimitra Kousi, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Antiviral Research|December 9, 2017
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countriesHakan Leblebicioglu, Joop E Arends, Resat Ozaras, et al.
Influenza and Other Respiratory Viruses|August 15, 2024
Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|January 19, 2024
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, et al.
Microorganisms|July 2, 2021
Clinical Characteristics of Patients with Tick-Borne Encephalitis (TBE): A European Multicentre Study from 2010 to 2017Benno Kohlmaier, Nina A Schweintzger, Manfred G Sagmeister, et al.
Influenza and Other Respiratory Viruses|March 9, 2025
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024Liliana Antunes, Madelyn Rojas-Castro, Marcos Lozano, et al.
Iscience|December 11, 2025
Genome-wide association study identifies <i>ABCG1</i> as a susceptibility locus for tick-borne encephalitisPiyush G Gampawar, Manfred G Sagmeister, Daniel Růžek, et al.
BMC Medicine|November 4, 2025
Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24Angela Mary Catherine Rose, Nathalie Nicolay, Clara Mazagatos, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 23, 2024
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024Marine Maurel, Jennifer Howard, Esther Kissling, et al.
Vaccine|May 20, 2023
VACCELERATE Site Network: Real-time definition of clinical study capacity in EuropeJon Salmanton-García, Pauline Wipfler, Paula Valle-Simón, et al.
Vaccines|December 23, 2023
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE ConsortiumDimitrios Poulimeneas, Markela Koniordou, Dimitra Kousi, et al.
Pageof 9